|
|
颇尔公司的呼吸过滤器有助于对患者及医务工作者的保护
作者：针刀培训… 点击数： 更新时间：2006-01-12 15:10:12 【字体：小 大】
|
(BW)(NY-PALL)(PLL)预防流行性感冒爆发：颇尔公司的呼吸过滤器有助于对患者及医务工作者的保护
美国商业新闻2006年1月9日纽约州东山消息——
2003年春，呼吸道病毒SARS在24个小时之内漫延了五个国家。死亡的人多数是首次接诊者，主要是加拿大和台湾的医务工作者。戴着呼吸器的SARS患者污染了设备，使没有采取防护措施的医务人员及随后的患者感染了这种致命性病毒。同样的情形也出现在禽流感传播过程中。
据世界卫生组织（WHO）透露，没有人能够预测到下一次流行性感冒会在什么时候爆发。不过，生物医学专家一致认为，流行性感冒的爆发不可避免，他们正密切关注欧洲、亚洲的H5N1（禽流感A）的形势，因为禽流感病毒有可能会更加容易和更加广泛地开始在人与人之间传播。美国卫生及公共服务部（Department of Health and Human Services）估计，只要爆发严重的流行性感冒，就可能会有9000万美国人受感染，近200万人可能会因此死亡。它们估计，1000万人将接受治疗。许多人一提到呼吸道疾病，可能会要求用呼吸器来帮助他们呼吸，然而目前呼吸器的供货也相当紧张。即便有了足够的呼吸器和呼吸设备，威胁依然存在。传统的消毒方法不能杀死SARS病毒或流行性感冒病毒。实际上，人们已经发现了SARS病毒可以在物体表面存活的时间，在塑料和不锈钢表面能够存活达72个小时，在玻璃表面可以存活96个小时。
尽管禽流感预防和媒体关注的焦点都集中在疫苗开发和抗病毒药物及抗生素的储备上，但是在医院感染的威胁依然存在。基于对SARS爆发的密切观察，公共卫生部门认识到医院现在采取的许多措施有助于保护患者和医务工作者免受可能威胁人类健康的禽流感及其他传染性病毒的感染。
此类措施之一就是使用呼吸系统过滤器，阻止病毒和细菌感染患者和医务工作者及污染呼吸设备。为了防止SARS的进一步传播，加拿大和台湾的卫生官员要求医院使用高效的呼吸循环过滤器，这些过滤器可以有效地捕获和保留有害病毒，防止交叉感染。他们还认识到只有那些符合严格标准，特别是防水以及具备高水平的病毒保护能力的过滤器才是行之有效的。
由于流行性感冒可以通过空气中的微粒及被污染的液体，诸如唾液和支气管分泌物等途径进行传播，因此这些标准对流行性感冒甚至更加紧急。颇尔公司（Pall Corporation）（纽约证券交易所：PLL）针对医院及呼吸保健部门的呼吸系统过滤器结合了这些严格要求，提供了一个行之有效的屏障，阻止病毒和细菌传播，并得到了国际卫生部门的特别推荐。
颇尔公司医疗总监兼纽约Albert Einstein医学院临床医学和儿科教授、医学博士Joseph Cervia说：“为了有效地阻止细菌和病毒传播，该呼吸过滤器必须应对各种潜在的传播途径，空气传播或液体传播。”
颇尔公司进行了广泛的过滤测试，测试显示了其呼吸系统过滤器能够有效地阻断这些传播途径。研究显示，颇尔公司的呼吸系统过滤器有效地阻断了被污染液体的疾病传播途径，空气传播的细菌及病毒去除率至少在99.999%。这些过滤器受到了细菌（缺陷短波单胞菌）和病毒（MS-2抗菌素）有机体的挑战，这是针对病菌去除程度的良好标准。
Cervia博士补充道：“基于该数据以及禽流感病毒的多少，我们认为我们的过滤器是一个有助于阻断流行性感冒传播途径的一种有效的方法。”
禽流感流行显然对全球卫生系统造成了很大的压力，医院工作者可能会因为患病而减员，呼吸器装置等科技资源供应短缺不能满足患者增加的需求。世界卫生组织表示，尽管先前发出了警告，但是当前全球在全球流行性感冒爆发期间预防流感的准备还很不充分。全球、国家及地方性卫生部门及机构将需要自我提高对流行性感冒爆发危险性的认识，采取措施努力确保集中充分的资源优化对此类疾病的预防。
据美国疾病控制与预防中心（CDC）的数据，不管禽流感是否爆发，Cervia博士都提醒我们每年近5－20%的美国人得流行性感冒，20多万人因患与流行性感冒有关的并发症接受治疗，近3.6万人因此而死亡。他说：“颇尔公司的呼吸系统过滤器可以在使传播可能性最小化方面发挥关键性作用，应该是每年传染性疾病预防过程中一个不可或缺的组成部分。”
颇尔公司为各种卫生应用提供范围广泛的呼吸系统过滤器，其中包括长期和短期以及医院设备用呼吸器。除了呼吸系统过滤器外，颇尔还提供了广泛的技术“安全网”，帮助减少在医院的感染。全球许多国家的医院都开始使用Pall-Aquasafe?过滤器，来降低患者感染危险性水生微生物的风险，如医院水系统中的军团菌。颇尔公司还提供用来保护输血安全的过滤器，免受患者感染病原体，其中包括感染“疯牛病”朊病毒。在相关领域，颇尔公司的技术还应用于生物制药领域的开发和生产过程中，其中包括抗病毒药物和疫苗，在那里它们将帮助确保无污染地快速生产。
专家讨论流行性感冒预防
为帮助应对流行性感冒的爆发，包括来自美国疾病控制与预防中心的专家及加拿大紧急疾病流行省级委员会（Canadian Critical Care Pandemic Provincial Committee）专家在内，国际专家将在一次全球网上互动电话会议上讨论流行性感冒的危险性及预防措施，这次会议由颇尔公司（纽约证券交易所：PLL）赞助，将于2006年1月18日举行。被命名为“流行病预防：流行性感冒的传播、其他流行病预防以及呼吸过滤器在医疗设备中的作用”的此次网上技术交流会主要针对卫生系统及可能被禽流感病毒等传染性疾病影响的卫生系统及领域，特别针对第一接诊者、急救病房医生、传染病控制人员、麻醉师、外科大夫、呼吸及肺部专家、护士及公共卫生官员。
发表演说的人包括美国疾病控制与预防中心国家传染病卫生质量推进部及学科代理联合总监、医学博士、公共卫生硕士Daniel B. Jernigan，他将发表有关流行性感冒传播途径及最新禽流感状况的观点；紧急疾病流行治疗类选法省级委员会（Critical Care Pandemic Triage Provincial Committee）及多伦多大学医学部医学博士、加拿大皇家医学院院士（FRCPC）Laura Hawryluck，将发表有关从SARS爆发吸取的教训；德国哥丁根医学院麻醉技术系理学博士Klaus Zuchner以及瑞士巴塞尔医学院流行病系医学博士Andreas Widmer，主要发表有关临床经验及呼吸循环过滤器作为阻断微生物传播途径的有效性的观点。
关于颇尔公司
颇尔公司是快速成长的过滤、分离及净化领域里的全球领先企业。颇尔公司的业务主要分布于两大广阔的市场：生命科学和工业。公司提供一流的产品，满足生物工艺学、医药品、输血、半导体、水净化、航空以及广泛的工业市场领域里客户要求严格的需要。公司2005财年总收入为19亿美元。公司总部位于纽约州东山，在全球各地广泛开展业务。访问颇尔公司的网站 http://www.pall.com/ 。
编者注：
网上技术交流会注册：“流行病预防”会议将于2006年1月18日美国东部时间上午10点（格林维治标准时间下午3点）举行。会议将持续近一个小时，包括互动的提问与回答。
卫生部门专家可以注册参加此次会议，注册可以通过以下链接：http://invite.mshow.com/findshow.aspx?usertype=1&cobrand=100&shownumber=266838（由于该链接过长，该URL可能必须复制/粘贴到你的互联网浏览器的地址栏中。如果中间有空格，请删除）。
邀请媒体聆听此次会议。根据计划，将专门安排媒体提问及对演说者的采访。联系Marcia_Katz@pall.com。
相关图片及更多有关颇尔公司呼吸系统过渡器系列及禽流感信息，可以登陆网站 http://www.pall.com/corporate_38842.asp 查询。
多媒体资讯：http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5051677
联系方式：颇尔公司（Pall Corporation）
媒体： Marcia Katz, 516-801-9128
传真：516-484-3649 marcia_katz@pall.com
或者
投资者关系部： Patricia Iannucci，516-801-9100
传真：516-484-3649 pat_iannucci@pall.com
(BW)(NY-PALL)(PLL) Influenza Pandemic Preparedness: Pall Breathing Filters Can Help Safeguard Patients and Healthcare Workers
EAST HILLS, N.Y.--(BUSINESS WIRE)--Jan. 9, 2006--
In the spring of 2003, the respiratory virus SARS traveled to five countries within 24 hours. Many of those who died were first responders - principally Canadian and Taiwanese healthcare workers. SARS patients on ventilators infected the equipment, inadvertently exposing hospital staff and subsequent patients to the deadly virus. The same scenario looms for avian flu.
According to the World Health Organization (WHO), no one can predict when the next influenza pandemic might occur. However biomedical experts agree that the occurrence of one is inevitable, and are watching the H5N1 (avian influenza A) situation in Europe and Asia very closely for the possibility that the virus may begin to spread more easily and widely from person to person. In the U.S., the Department of Health and Human Services estimates that with a severe flu pandemic, 90 million Americans would become ill and nearly two million would die. They estimate that as many as 10 million people would be hospitalized. Presenting with respiratory illness, many may require ventilators--already in short supply--to help them breathe. Even with sufficient ventilators and respiratory equipment, a threat remains. Traditional disinfection methods do not destroy the SARS or influenza viruses. In fact, the SARS virus was found to live on surfaces for prolonged periods of time, up to 72 hours on plastic and stainless steel and 96 hours on glass slides.
Although avian flu preparedness and media attention is focused on vaccine development and stockpiling of antiviral medicines and antibiotics, the threat of nosocomial (hospital-acquired) infection remains significant. Based on key observations from the SARS outbreak, the public health community recognizes that there are a number of measures hospitals can take now to help safeguard patients and staff from avian flu and other infectious viruses that could threaten global health.
One such measure is the use of breathing system filters as a barrier between viral and bacterial transmission to patients, hospital staff and respiratory equipment. To prevent further SARS contamination, health officials in Canada and Taiwan issued directives to hospitals to use high-efficiency breathing circuit filters that effectively capture and retain the offending virus to prevent cross-contamination. They also recognized that only filters that meet stringent criteria, specifically being hydrophobic (ability to repel liquids) and also demonstrating high levels of viral retention, would be effective.
These criteria are even more critical with influenza, due to its likely modes of transmission -- through droplets in the air and contaminated fluids, such as saliva and bronchial secretions. Pall Corporation’s (NYSE: PLL) breathing system filters for anesthesia and respiratory care combine these stringent requirements to provide an effective barrier against viral and bacterial contaminants, and were specifically recommended by international health authorities.
"In order to be an effective barrier to bacterial and viral transmission, the breathing filters must respond to a variety of potential routes of transmission, both airborne and liquid," says Joseph Cervia, MD, Professor of Clinical Medicine and Pediatrics at Albert Einstein College of Medicine, New York and Medical Director of Pall Corporation.
Pall has conducted extensive validation testing to show that its breathing system filters can be an effective barrier for these routes of transmission. Studies have shown that Pall Breathing System Filters provide an effective barrier to contaminated liquids and have an airborne bacterial and viral removal efficiency of at least 99.999 percent. The filters have been challenged with bacterial (Brevundimonas diminuta) and viral (MS-2 bacteriophage) organisms that represent the gold standard for pathogen exclusion on the basis of size.
"Based on the data and the size of the avian flu virus, we believe our filters can be an effective way to help eliminate the passage of influenza virus," Dr. Cervia adds.
An avian flu pandemic would obviously put a great strain on healthcare systems worldwide, with hospital staff likely to be reduced by illness and technological resources, such as mechanical ventilators in relatively short supply for meeting the increased patient demand. The WHO has stated that despite advance warning, the world is currently ill prepared to defend itself during a global flu pandemic. Global, national, and local healthcare authorities and providers will need to educate themselves on the risks of pandemic influenza, and lead the way in efforts to assure that adequate resources are focused upon measures that will optimize preparedness for such an event.
Whether or not there is an avian flu pandemic, Dr. Cervia reminds us that each year approximately 5 to 20 percent of U.S. residents get the flu, more than 200,000 are hospitalized for flu-related complications and about 36,000 Americans die, according to the CDC. He says, "Pall Breathing System Filters can play a key role in minimizing exposure and should be an integral part of infectious disease preparedness every year."
Pall provides a range of breathing system filters for a variety of healthcare applications including mechanical ventilation, both long and short-term use as well as for anesthesia equipment. In addition to breathing system filters, Pall provides a broad "safety net" of technologies to help reduce nosocomial infections. Hospitals in a number of countries around the world are turning to the Pall-Aquasafe(TM) filters to reduce patient exposure to dangerous waterborne microorganisms such as Legionella from their water systems. Pall also provides filters to protect the blood supply from pathogens, including infectious "mad cow" prions. In a related area, Pall technologies are used in the development and processing of biopharmaceuticals including antiviral medicines and vaccines, where they help ensure purity and speed production.
Experts Speak Out on Pandemic Preparedness
To help prepare for an influenza outbreak, international experts including representatives from the U.S. Centers for Disease Control and Prevention (CDC) and the Canadian Critical Care Pandemic Provincial Committee will discuss influenza risks and protective measures in a global web-based interactive teleconference, sponsored by Pall Corporation (NYSE: PLL), on January 18, 2006. The webinar entitled "Pandemic Preparedness: Transmission of Influenza and Other Infectious Disease and the Role of Breathing Filters in the Clinical Setting" is designed for healthcare systems and disciplines likely to be affected by infectious diseases, such as avian flu. It is especially relevant to first responders, emergency room physicians, infection control officers, anesthesiology practitioners, surgeons, respiratory and pulmonary specialists, nurses and public health officials.
Speakers include Daniel B. Jernigan, M.D., MPH, Acting Associate Director for Science, Division of Healthcare Quality Promotion National Center for Infectious Disease, U.S. Centers for Disease Control and Prevention, providing an overview on the routes of influenza transmission and an update on avian flu; Laura Hawryluck, M.D., MSc, FRCPC from the Faculty of Medicine at the University of Toronto and the Critical Care Pandemic Triage Provincial Committee, on applying lessons learned from the SARS outbreak; Klaus Zuchner, Ph.D., Department of Anaesthesia Technology, University Hospital, Gottingen, Germany; and Andreas Widmer, M.D., Division of Infectious Diseases, University Hospital, Basel, Switzerland, covering both clinical experience and microbiological benefits of breathing circuit filtration as a barrier to transmission.
About Pall Corporation
Pall is the global leader in the rapidly growing field of filtration, separations and purification. Pall’s business is organized around two broad markets: Life Sciences and Industrial. The Company provides leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceuticals, transfusion medicines, semiconductors, water purification, aerospace and broad industrial markets. Total revenue for fiscal 2005 were $1.9 billion. The Company headquarters are in East Hills, New York, with extensive operations throughout the world. Visit Pall at www.pall.com.
Editor’s Notes:
Webinar Registration: "Pandemic Preparedness" will be held on January 18, 2006, 10:00 AM EST (3:00 PM GMT). The conference will be approximately one hour in length and include an interactive Q&A.
Healthcare professionals can register to participate at the following link http://invite.mshow.com/findshow.aspx?usertype=1&cobrand=
100&shownumber=266838 (Due to its length, this URL may need to be copied/pasted into your Internet browser’s address field. Remove the extra space if one exists).
Media are invited to listen in. Special arrangements will be made for responding to media questions and interviews with speakers where schedules permit. Contact Marcia_Katz@pall.com.
Photos and more information on Pall’s family of Breathing System Filters and avian flu can be found on http://www.pall.com/corporate_38842.asp
MULTIMEDIA AVAILABLE:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5051677
CONTACT: Pall Corporation Media: Marcia Katz, 516-801-9128 Fax: 516-484-3649 marcia_katz@pall.com OR Investor Relations: Patricia Iannucci, 516-801-9100 Fax: 516-484-3649 pat_iannucci@pall.com
|
|
|
|
|
